Key result
Inhaled treprostinil slowed the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis, though benefits may not be uniform across subgroups.
Why the study?
Does inhaled treprostinil reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis?
Does inhaled treprostinil reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis?
While inhaled treprostinil slows FVC decline in IPF, authors suggest further investigation is needed to identify subgroup-specific responses.
To the Editor: The recently published results of the TETON-1 and TETON-2 trials by Nathan and colleagues (July 9 issue) 1,2 showed that inhaled treprostinil slowed the decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF), findings that support a potential antifibrotic effect. However, we believe that these results need further investigation to assess whether the benefits of inhaled treprostinil extend to all patients with IPF or are confined to specific subgroups, thereby necessitating a personalized approach. Previous evidence suggests that the response to inhaled treprostinil may not be uniform across patients with interstitial lung disease. 3 The . . .
No takes yet. Share an insight, caveat, or question.
Karampitsakos et al. (2026) conducted a letter in Idiopathic pulmonary fibrosis. Inhaled treprostinil was evaluated on Decline in forced vital capacity (FVC). Inhaled treprostinil slowed the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis, though benefits may not be uniform across subgroups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: